209627-36-1

Basic information

• Product Name: (2S)-2-(((tert-butyldiphenylsilyl)oxy)methyl)idinepyrrol
• Synonyms: (2S)-2-(((tert-butyldiphenylsilyl)oxy)methyl)idinepyrrol
• CAS NO: 209627-36-1
• Molecular Weight: 339.553
• Mol File: 209627-36-1.mol

Chemical Properties

• CAS DataBase Reference: (2S)-2-(((tert-butyldiphenylsilyl)oxy)methyl)idinepyrrol(CAS DataBase Reference)
• NIST Chemistry Reference: (2S)-2-(((tert-butyldiphenylsilyl)oxy)methyl)idinepyrrol(209627-36-1)
• EPA Substance Registry System: (2S)-2-(((tert-butyldiphenylsilyl)oxy)methyl)idinepyrrol(209627-36-1)

Safety Data

• Hazardous Substances Data: 209627-36-1(Hazardous Substances Data)

Usage

Uses

Used in Organic Synthesis:
(2S)-2-(((tert-butyldiphenylsilyl)oxy)methyl)idinepyrrol is used as a reagent or intermediate for the synthesis of other pyrrolidine derivatives, providing a versatile building block for the creation of complex organic molecules.
Used in Medicinal Chemistry:
In the field of medicinal chemistry, (2S)-2-(((tert-butyldiphenylsilyl)oxy)methyl)idinepyrrol is utilized for the development of pharmaceutical compounds, taking advantage of its chiral properties and protective silyl group to create enantiomerically pure drugs with desired biological activities.
Used in Materials Science:
(2S)-2-(((tert-butyldiphenylsilyl)oxy)methyl)idinepyrrol is employed in materials science for the design and synthesis of novel materials with specific properties, such as chiral polymers or other functional materials, leveraging its unique structural features and reactivity.
Used in Protective Group Chemistry:
The tert-butyldiphenylsilyl group in (2S)-2-(((tert-butyldiphenylsilyl)oxy)methyl)idinepyrrol serves as a protective group, allowing chemists to selectively manipulate the pyrrolidine ring during chemical reactions. This selective protection is crucial in complex organic synthesis, where the preservation of specific functional groups is necessary to achieve the desired final product.

Upstream product

• 87727-28-4 (S)-2-tert-butyl-dimethyl-silanyloxy propanal 
• 1355017-06-9 C₂₉H₃₅NOSi 
• 1355017-01-4 C₂₈H₃₉NOSi 
• 1355016-97-5 C₃₁H₃₇NOSi 
• 1355016-96-4 C₃₀H₃₅NOSi 
• 1355016-90-8 C₃₁H₃₇NO₃Si 
• 1355016-92-0 C₂₇H₃₇NO₃Si 
• 1355016-94-2 C₂₆H₃₅NOSi 
• 1355016-95-3 C₂₇H₃₇NOSi 
• 1355016-93-1 C₂₅H₃₅NOSi 
• 1355016-91-9 C₂₈H₃₉NOSi 
• 948992-89-0 (S)-2-((tert-butyldiphenylsilyloxy)methyl)-1-chloropyrrolidine 
• 58479-61-1 tert-butylchlorodiphenylsilane 
• 23356-96-9 (S)-1-Pyrrolidin-2-yl-methanol 

Downstream Products

• 854443-30-4 N^δ-(allyloxycarbonyl)-N^α-(fluoren-9-ylmethoxycarbonyl)-L-ornithyl-O-(tert-butyldiphenylsilyl)-L-prolinol 
• 948992-89-0 (S)-2-((tert-butyldiphenylsilyloxy)methyl)-1-chloropyrrolidine 
• 1355016-90-8 C₃₁H₃₇NO₃Si 
• 1355016-92-0 C₂₇H₃₇NO₃Si 
• 1355016-95-3 C₂₇H₃₇NOSi 
• 1355017-01-4 C₂₈H₃₉NOSi 
• 1355016-97-5 C₃₁H₃₇NOSi 
• 1355016-93-1 C₂₅H₃₅NOSi 
• 1355016-94-2 C₂₆H₃₅NOSi 
• 1355017-06-9 C₂₉H₃₅NOSi 
• 1355016-96-4 C₃₀H₃₅NOSi 
• 108-94-1 cyclohexanone 
• 583-60-8 2-Methylcyclohexanone 
• 1355016-91-9 C₂₈H₃₉NOSi 

Relevant articles and documents

COMPOUNDS AND METHODS FOR TARGETED DEGRADATION OF KRAS

Bifunctional compounds, which find utility as modulators of Kirsten ras sarcoma protein (KRas or KRAS), are described herein. In particular, the hetero-bifunctional compounds of the present disclosure contain on one end a moiety that binds to the Von Hippel-Lindau E3 ubiquitin ligase and on the other end a moiety which binds KRas, such that the target protein is placed in proximity to the ubiquitin ligase to effect degradation (and inhibition) of target protein. The heterobifunctional compounds of the present disclosure exhibit a broad range of pharmacological activities associated with degradation/inhibition of target protein. Diseases or disorders that result from aberrant regulation of the target protein are treated or prevented with compounds and compositions of the present disclosure.

Tetrahydropyridopyrimidine compound with anti-tumor activity

The invention provides a tetrahydropyridopyrimidine compound shown as a formula (I) or a pharmaceutically acceptable salt thereof, a pharmaceutical composition containing the tetrahydropyridopyrimidine compound and the pharmaceutically acceptable salt thereof, and application of the tetrahydropyridopyrimidine compound or the pharmaceutically acceptable salt thereof in the preparation of a drug forpreventing and/or treating KRAS G12C mutant tumors.

HETEROCYCLIC COMPOUNDS AS INHIBITORS OF PLATELET AGGREGATION

The present invention provides compounds of Formula I: wherein Y, AA, W, R3, R2, R4, R5, R6, R7, X1, X2, X3, X4 and X5 are as defined herein, or a stereoisomer, tautomer, pharmaceutically acceptable salt, prodrug or esters or solvate form thereof, wherein all of the variables are as defined herein. These compounds are inhibitors of platelet aggregation and thus can be used as medicaments for treating or preventing thromboembolic disorders.

MACROCYCLIC LRRK2 KINASE INHIBITORS

The present invention relates to novel macrocyclic compounds of formula (I) and compositions containing said compounds acting as kinase inhibitors, in particular as inhibitors of LRRK2 (Leucine-Rich Repeat Kinase 2). Moreover, the present invention provides processes for the preparation of the disclosed compounds, as well as methods of using them, for instance as a medicine or diagnostic agent, in particular for the treatment and/or diagnosis of diseases characterized by LRRK2 kinase activity such as neurological disorders including Parkinson's disease and Alzheimer's disease.

Transfer of 1-alkenyl groups between secondary amines. Relative stability and reactivity of enamines from popular organocatalysts

Enamines from 3-methylbutanal and several Pro- and Phe-derived secondary amines were prepared in DMSO-d6, CD3CN, and CDCl 3. For the first time, the relative thermodynamic stabilities of these and other enamines were compared, and rapid exchanges of 1-alkenyl groups were demonstrated. Competition experiments showed that the most favored enamines (without significant steric inhibition of resonance) react more rapidly with electrophiles.

Relative tendency of carbonyl compounds to form enamines

Equilibria between carbonyl compounds and their enamines (from O-TBDPS-derived prolinol) have been examined by NMR spectroscopy in DMSO-d 6. By comparing the exchange reactions between pairs (enamine A + carbonyl B → carbonyl A + enamine B), a quite general scale of the tendency of carbonyl groups to form enamines has been established. Aldehydes quickly give enamines that are relatively more stable than those of ketones, but there are exceptions to this expected rule; for example, 1,3-dihydroxyacetone acetals or 3,5-dioxacyclohexanones (2-phenyl-1,3-dioxan-5-one and 2,2-dimethyl-1,3- dioxan-5-one) show a greater tendency to afford enamines than many α-substituted aldehydes.

Prolinol tert-butyldiphenylsilyl ether as organocatalyst for the asymmetric michael addition of cyclohexanone to nitroolefins

The direct Michael additions of cyclohexanone to nitroolefins catalyzed by prolinol tert-butyldiphenylsilyl ether were conducted successfully in good yields (up to 99%) and high stereo-selectivities (up to 98:2 diastereomeric ratio and 95% enantiomeric ex

Total synthesis of the putative structure of stemonidine: The definitive proof of misassignment

The total synthesis of the putative structure of the Stemona alkaloid stemonidine has been completed. The key transformations include a 1,3-dipolar cycloaddition of a chiral nitrone derived from (S)-prolinol and a spirolactonization process involving the

Synthesis and biological evaluation of conformationally constrained analogues of the antitubercular agent ethambutol

Three (S)-prolinol-derived conformationally restricted analogues of the antitubercular agent ethambutol were prepared and tested against Mycobacterium tuberculosis.

Synthesis of a β-turn mimetic suitable for incorporation in the peptide hormone LHRH

LHRH is a decapeptide hormone which plays a central role in neuroendocrinology. Conformational studies have suggested that LHRH may adopt a β-turn involving residues 5-8 when bound to its receptor. A β-turn mimetic with side chains corresponding to those of a Tyr-Gly-Leu-Orn tetrapeptide has therefore been synthesized for incorporation at positions 5-8 in LHRH. In the turn mimetic, residues i and i+1 are connected by a ψ[CH2O] isostere instead of an amide bond, while a covalent ethylene bridge replaces the hydrogen bond which is often found between residues i and i+3 in β-turns. The turn mimetic was assembled from three types of building blocks: an azido aldehyde, an Fmoc protected amino acid and a protected dipeptide amine.